In preclinical studies, human CD4+CD25+CD127− Tregs have been shown to be effective in preventing Graft vs. Host Disease (GvHD) (9, 10), autoimmune diseases (11, 12) and delaying graft rejection (13, 14). This evidence concerns the gene IL2RA and autoimmune disease.